Table 1.
Range used in sensitivity analysis and the rationale for use
| No. | First author, year | Distinct uncertain parameters | Range used in sensitivity analysis | Rationale |
|---|---|---|---|---|
| 1 | Aponte-Gonzalez et al. 2013 [20] | CVG | Bivalent vaccine: US$133–487 Quadrivalent vaccine: US$157–282 |
Range of vaccine cost was to determine threshold price at which vaccine will be cost-effective |
| 2 | Berkhof et al. 2013 [21] | None | – | – |
| 3 | Campos et al. 2012 [22] | CVG, vaccine coverage | CVG: I$5–200 Vaccine coverage: base coverage of 70 % and attrition rate per dose of 15 % varied from 0 to 40 % |
Range of CVG was to determine threshold price at which vaccine will be cost-effective since CVG was unknown. Vaccine coverage was assumed |
| 4 | Canfell et al. 2011 [23] | None | – | – |
| 5 | Colantonio et al. 2009 [24] | None | – | – |
| 6 | Diaz et al. 2008 [25] | CVG | CVG: I$5–360 | Range of CVG was to determine threshold price at which vaccine will be cost-effective since CVG was unknown |
| 7 | Fonseca et al. 2013 [26] | CVG, vaccine coverage | CVG: US$15–500 Vaccine coverage: 30–100 % |
Range of CVG and vaccine coverage were authors’ judgment regarding uncertainty associated with parameters |
| 8 | Ginsberg et al. 2009 [27] | CVG | CVG: US$1.8–6 (i.e. US$0.6–2 per dose) | Range of CVG was assumed |
| 9 | Goldie et al. 2007 [30] | CVG, vaccine coverage | CVG: I$25–450 Vaccine coverage: 10–100 % |
Range of CVG was to determine threshold price at which vaccine will be cost-effective since CVG was unknown. Range of vaccine coverage was assumed |
| 10 | Goldie et al. 2008 [28] | CVG, vaccine coverage | CVG: I$5–430 Vaccine coverage: 0–90 % |
Range of CVG was to determine threshold price at which vaccine will be cost-effective since CVG was unknown. Range of vaccine coverage was assumed |
| 11 | Goldie et al. 2008 [29] | CVG | CVG: I$5–360 | Range of CVG was to determine threshold price at which vaccine will be cost-effective since CVG was unknown |
| 12 | Goldie et al. 2008 [32] | CVG | CVG: I$5–50 | Range of CVG was to determine threshold price at which vaccine will be cost-effective since CVG was unknown |
| 13 | Goldie et al. 2012 [31] | None | – | – |
| 14 | Gutierrez-Aguado, 2011 [33] | None | – | – |
| 15 | Gutierrez-Delgado et al. 2008 [34] | CVG | CVG: US$15.9–80 per dose | Range of vaccine cost was to determine threshold price at which vaccine will be cost-effective |
| 16 | Insinga et al. 2007 [35] | Vaccine coverage | Vaccine coverage: 20–85 % | Range of vaccine coverage was assumed |
| 17 | Jit et al. 2014 [36] | Not applicable | – | – |
| 18 | Kawai et al. 2012 [37] | None | – | – |
| 19 | Khatibi et al. 2014 [38] | None | – | – |
| 20 | Kiatpongsan and Kim, 2014 [39] | Not applicable | – | – |
| 21 | Kim et al. 2007 [40] | CVG | CVG: I$25–400 | Range of CVG was to determine threshold price at which vaccine will be cost-effective since CVG was unknown |
| 22 | Kim et al. 2008 [42] | CVG, vaccine and screening coverage | CVG: I$10–450 Vaccine coverage: 20–100 % Screening coverage: 20–100 % |
Range of CVG was to determine threshold price at which vaccine will be cost-effective since CVG was unknown. Ranges of vaccine and screening coverage rate were assumed |
| 23 | Kim et al. 2011 [44] | Not applicable | – | – |
| 24 | Kim et al. 2013 [41] | CVG | CVG: I$5–360 | Range of CVG was to determine threshold price at which vaccine will be cost-effective since CVG was unknown |
| 25 | Kim et al. 2013 [43] | CVG | CVG: I$5–500 | Range of CVG was to determine threshold price at which vaccine will be cost-effective since CVG was unknown |
| 26 | Levin et al. 2015 [45] | None | – | – |
| 27 | Praditsitthikorn et al. 2011 [46] | CVG, screening coverage | CVG: Bt3530–15,000 (I$290–1233) Screening coverage: 20–80 % |
Range of CVG was to determine threshold price at which vaccine will be cost-effective. Range of screening coverage was assumed |
| 28 | Reynales-Shigematsu et al. 2009 [47] | CVG, Vaccine coverage | CVG: US$45–250 Vaccine coverage: 0–100 % |
Range of CVG was to determine threshold price at which vaccine will be cost-effective since CVG was unknown. Range of vaccine coverage rate was assumed |
| 29 | Sharma et al. 2012 [48] | CVG | CVG: I$10–500 | Range of CVG was to determine threshold price at which vaccine will be cost-effective since CVG was unknown |
| 30 | Sinanovic et al. 2009 [49] | CVG | CVG: US$192–480 per dose | Range of CVG was to determine threshold price at which vaccine will be cost-effective |
| 31 | Termrungruanglert et al. 2012 [50] | CVG | CVG: Bt6189–12,378 (US$177–354) | Authors did not specify how CVG was estimated, nor the reason for the range used in sensitivity analysis |
| 32 | Tracy et al. 2014 [51] | None | – | – |
| 33 | Vanni et al. 2012 [52] | CVG | CVG: US$25–556 (US$5–120 per dose) | Range of CVG was to determine threshold price at which vaccine will be cost-effective since CVG was unknown |
Bt Baht, CC cervical cancer, CVG cost per vaccinated girl, HPV human papillomavirus, I$ international dollars, US$ US dollars